NSCLC, Stage I Clinical Trials

NCT ID: NCT06404164 Recruiting - NSCLC, Stage I Clinical Trials

Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection

Start date: January 30, 2022
Phase: N/A
Study type: Interventional

A method of ICG counterstaining localization under target artery occlusion without cutting，It's a new method of localization of small pulmonary nodules.

NCT ID: NCT05686434 Recruiting - NSCLC, Stage I Clinical Trials

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Start date: October 14, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).

NCT ID: NCT04830826 Recruiting - NSCLC, Stage III Clinical Trials

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

Start date: June 10, 2020
Phase:
Study type: Observational

This study is a prospective, national, multi-center, non-interventional study. The main purpose is to explore the initial adjuvant treatment pattern after radical resection for early-stage NSCLC patients with EGFR Mutation-Positive in the real world. The secondary purpose was to observe the postoperative follow-up treatment pattern and its subgroups (based on different EGFR mutation status and different clinical stages).

NCT ID: NCT04317534 Recruiting - NSCLC, Stage I Clinical Trials

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: - Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles - Arm B: Observation Stratification factors will include: PD-L1 TPS (<50% vs. ≥50%), and tumor size (1-2 cm vs. >2-4 cm)

NCT ID: NCT04205552 Recruiting - NSCLC, Stage I Clinical Trials

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

NEOpredict

Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.

NCT ID: NCT03454685 Recruiting - Healthy Subjects Clinical Trials

The Role of Microbiota on the Development of Lung Cancer

Start date: January 30, 2018
Phase:
Study type: Observational

Relationship between human microbiota and epidemiology of lung cancer

NCT ID: NCT03446547 Recruiting - NSCLC, Stage I Clinical Trials

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

ASTEROID

Start date: December 4, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized multicentre open label phase II study of Durvalumab following Stereotactic Body Radiotherapy (SBRT) in patients with T1-2N0M0 NSCLC. Patients will be randomized 1:1 to follow up or receiving Durvalumab every 4th week for 12 months

NSCLC, Stage I clinical trials